FDA closes Dr. Reddy's Bachupally FTO-3 inspection as VAI: what it means
Dr. Reddy's says the US regulator classified its Hyderabad formulations plant as Voluntary Action Indicated and closed the inspection. The details behind the label are not public in the record.
What happened
Dr. Reddy's Laboratories says the US Food and Drug Administration has classified its inspection of the Bachupally FTO-3 formulations plant in Hyderabad as Voluntary Action Indicated (VAI). The company also says the agency considers the inspection officially closed. The information comes from the company's own disclosure filed with the US Securities and Exchange Commission.
The record does not say when the inspection took place, how long it ran, or how many observations were issued. It does not say what those observations covered or which products are made at the site. It also does not include any FDA statement. Everything here rests on the company's account of the agency's decision.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- USFDA closes Dr. Reddy's Bachupally FTO-3 inspection with Voluntary Action Indicated status Dr Reddys Laboratories Ltd · Mon 16 Nov 2026
- BfArM publishes Philips urgent field safety notice for IntraSight Plus ultrasound system BfArM field safety notices · Mon 16 Nov 2026
- BfArM publishes Medtronic urgent field safety notice for Vanta implantable neurostimulator BfArM field safety notices · Mon 16 Nov 2026
- CMS proposes CRUSH rule to tighten fraud oversight across Medicare, Medicaid, CHIP and Marketplace CMS · Mon 16 Nov 2026
- BfArM lists urgent field safety notice for M.E.D. Medical Products Custom Pack BfArM field safety notices · Mon 16 Nov 2026
- BfArM publishes B. Braun urgent field safety notice for Pleuracan drainage device BfArM field safety notices · Mon 16 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.